Outcome of Transplantation for Acute Myelogenous Leukemia in Children with Down Syndrome
Outcome of Transplantation for Acute Myelogenous Leukemia in Children with Down Syndrome
复制标题
DOI：
10.1016/j.bbmt.2013.02.017
复制
发表时间：
2013-06-01
影响因子：
4.3
通讯作者：
Carpenter, Paul A.
中科院分区：
文献类型：
--
作者：
Hitzler, Johann K.;He, Wensheng;Carpenter, Paul A.
关于唐氏综合征和急性髓性白血病（DS-AML）患儿异基因移植结局的数据很少且相互矛盾。早期的报告强调治疗相关的死亡率是主要障碍;最近的病例系列指出移植后复发。我们回顾了2000年至2009年间向国际血液和骨髓移植研究中心报告的28例DS-AML患者的结局数据，并对21例DS-AML患者和80例非DS AML对照进行了首次配对分析。DS-AML移植时的中位年龄为3岁，几乎一半的队列处于第二次缓解期。3年总生存率仅为19%。在多变量分析中，调整从诊断到移植的时间间隔，复发风险（风险比[HR]，2.84; P
Data on outcomes of allogeneic transplantation in children with Down syndrome and acute myelogenous leukemia (DS-AML) are scarce and conflicting. Early reports stress treatment-related mortality as the main barrier; a recent case series points to posttransplantation relapse. We reviewed outcome data for 28 patients with DS-AML reported to the Center for International Blood and Marrow Transplant Research between 2000 and 2009 and performed a first matched-pair analysis of 21 patients with DS-AML and 80 non-DS AML controls. The median age at transplantation for DS-AML was 3 years, and almost half of the cohort was in second remission. The 3-year probability of overall survival was only 19%. In multivariate analysis, adjusting for interval from diagnosis to transplantation, risks of relapse (hazard ratio [HR], 2.84; P